Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study
Conclusions - the addition of venetoclax to patients with HMA-refractory AML may result in a substantial anti-leukemic activity, specifically in those achieving complete remission. This should be further tested in a well designed prospective trial.DisclosuresZuckerman: Cellect Biotherapeutics Ltd: Consultancy.
Source: Blood - Category: Hematology Authors: Ram, R., Amit, O., Zuckerman, T., Gurion, R., Raanani, P., Bar-On, Y., Avivi, I., Wolach, O. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bleeding | Chemotherapy | History of Medicine | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants